Trials / Unknown
UnknownNCT04803929
Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)
Clinical Study of Autologous T Cells Modified With ILT3 Chimeric Antigen Receptor for Relapsed/Refractory Acute Myeloid Leukemia (M4/M5)
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Carbiogene Therapeutics Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the safety and efficacy of novel ILT3-targeted CAR-T cell therapy for patients with relapsed or refractory acute myeloid leukemia (M4/M5).
Detailed description
Our group has developed a novel anti-ILT3 CAR T cell therapy, and this pilot study is focused on the safety and efficacy of the anti-ILT3 CAR-T for R/R AML(M4/M5) patients. A total of 25 subjects are intravenously adminstered with anti-ILT3 CAR-T cells. The dosages of CAR-T cells follow the "3+3" dose increment program.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | anti-ILT3 CAR-T | Autologous T cells genetically modified with anti-ILT3 CAR |
Timeline
- Start date
- 2021-03-03
- Primary completion
- 2024-03-01
- Completion
- 2026-03-01
- First posted
- 2021-03-18
- Last updated
- 2021-03-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04803929. Inclusion in this directory is not an endorsement.